Stress biomarkers in adult patients with drug-resistant epilepsy on a modified Atkins diet: A prospective study.


Journal

Epilepsia open
ISSN: 2470-9239
Titre abrégé: Epilepsia Open
Pays: United States
ID NLM: 101692036

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 10 02 2023
accepted: 21 07 2023
medline: 4 12 2023
pubmed: 14 8 2023
entrez: 13 8 2023
Statut: ppublish

Résumé

Ketogenic diets like the modified Atkins diet (MAD) are increasingly used in patients with refractory epilepsy. For epilepsy patients, stress is a well-known seizure-precipitating factor. New possibilities for measuring biomarkers of stress are now available. The purpose of this study was to investigate the impact of MAD on endocrine stress biomarkers. Forty-nine patients with drug-resistant epilepsy were investigated at baseline and after 12 weeks on MAD. Cortisol and cortisol-binding globulin (CBG) were measured and free cortisol index (FCI) calculated. We also measured metanephrine, normetanephrine, and methoxytyramine, all markers of epinephrine, norepinephrine, and dopamine, respectively. Changes were analyzed according to sex and antiseizure medications. The different markers at baseline and after 12 weeks of MAD treatment were correlated with seizure frequency and weight loss, respectively. The change in total cortisol was modest after 12 weeks on the diet (from 432.9 nmol/L (403.1-462.7)) to 422.6 nmol/L (384.6-461.0), P = 0.6). FCI was reduced (from 0.39 (0.36-0.42) to 0.34 (0.31-0.36), P = 0.001). CBG increased during the study (from 1126.4 nmol/L (1074.5-1178.3) to 1272.5 nmol/L (1206.3-1338.7), P < 0.001). There were no changes in the metanephrines after 12 weeks on the diet. The decrease in FCI was significant only in women, and only observed in patients using nonenzyme-inducing ASMs. We did not find any correlation between cortisol, CBG, or FCI levels and seizure frequency. After being on MAD for 12 weeks, FCI decreased significantly. The reduction in FCI may reflect reduced stress, but it may also be an effect of increased CBG. The reasons behind these alterations are unknown. Possibly, the changes may be a result of a reduction in insulin resistance and thyroid hormone levels. Treatment with MAD does not seem to influence "fight or flight" hormones.

Identifiants

pubmed: 37574592
doi: 10.1002/epi4.12808
pmc: PMC10690645
doi:

Substances chimiques

Hydrocortisone WI4X0X7BPJ

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1331-1339

Informations de copyright

© 2023 The Authors. Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.

Références

Neurosci Lett. 2021 Feb 16;746:135618
pubmed: 33429002
Epilepsy Behav. 2015 Dec;53:197-201
pubmed: 26588588
Epilepsy Behav. 2019 May;94:277-280
pubmed: 30999258
N Engl J Med. 2005 Oct 20;353(16):1711-23
pubmed: 16236742
Compr Physiol. 2016 Mar 15;6(2):603-21
pubmed: 27065163
Epilepsia Open. 2023 Dec;8(4):1331-1339
pubmed: 37574592
Cochrane Database Syst Rev. 2020 Jun 24;6:CD001903
pubmed: 32588435
Pharmacol Rev. 2004 Sep;56(3):331-49
pubmed: 15317907
Front Neurol. 2021 Jul 30;12:720073
pubmed: 34393987
Epilepsia. 2019 Nov;60(11):2235-2244
pubmed: 31602644
Epilepsy Behav. 2020 Oct;111:107285
pubmed: 32698106
Scand J Clin Lab Invest. 2019 Sep;79(5):314-319
pubmed: 31161807
Clin Exp Rheumatol. 2000 Mar-Apr;18(2):209-14
pubmed: 10812493
Neurosci Biobehav Rev. 2019 Aug;103:216-229
pubmed: 31129236
Dev Med Child Neurol. 2022 Nov;64(11):1330-1343
pubmed: 35765990
Epilepsia. 2018 Aug;59(8):1567-1576
pubmed: 29901816
Neurology. 2007 Nov 13;69(20):1905-10
pubmed: 17998482
Int Rev Neurobiol. 2020;152:195-219
pubmed: 32450996
Epilepsia. 2022 Apr;63(4):880-891
pubmed: 35092022
Eur J Endocrinol. 1995 May;132(5):594-8
pubmed: 7749500
Epilepsy Behav. 2005 Feb;6(1):85-9
pubmed: 15652738
Clin Chem. 2021 Aug 5;67(8):1098-1112
pubmed: 33993248
Lancet. 2019 Feb 16;393(10172):689-701
pubmed: 30686584
Cell Mol Neurobiol. 2012 Jul;32(5):737-48
pubmed: 22090159

Auteurs

Ellen Molteberg (E)

National Centre for Epilepsy, Oslo University Hospital, Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Per M Thorsby (PM)

Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Hormone Laboratory, Dep of Medical Biochemistry and Biochemical endocrinology and metabolism research group, Oslo University Hospital, Oslo, Norway.

Magnhild Kverneland (M)

National Centre for Epilepsy, Oslo University Hospital, Oslo, Norway.

Per Ole Iversen (PO)

Department of Nutrition, University of Oslo, Oslo, Norway.
Department of Haematology, Oslo University Hospital, Oslo, Norway.

Kaja K Selmer (KK)

National Centre for Epilepsy, Oslo University Hospital, Oslo, Norway.
Department of Research and Innovation, Division of Clinical Neuroscience, Oslo University Hospital and the University of Oslo, Oslo, Norway.

Dag Hofoss (D)

National Centre for Epilepsy, Oslo University Hospital, Oslo, Norway.

Karl O Nakken (KO)

National Centre for Epilepsy, Oslo University Hospital, Oslo, Norway.

Erik Taubøll (E)

Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Department of Neurology, Oslo University Hospital, Oslo, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH